How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Prescription Digital Therapeutics (PDT) Market
- By Therapeutic Area: Diabetes Management, Chronic Pain Management, Mental Health Disorders, Cardiovascular Diseases, Respiratory Diseases
- By End User: Hospitals and Clinics, Outpatient Care Centers, Home Healthcare Settings, Specialty Clinics, Primary Care Providers
- By Delivery Platform: Mobile Applications, Web-Based Platforms, Wearable Devices Integration, Virtual Reality Systems, Telehealth Integration
- By Reimbursement Model: Insurance-Covered PDTs, Out-of-Pocket Payment, Value-Based Reimbursement, Subscription-Based Models, Government-Funded Programs
- By Technology Type: Cognitive Behavioral Therapy (CBT) Based PDTs, Behavioral Modification PDTs, Medication Adherence PDTs, Remote Monitoring PDTs, Biofeedback PDTs
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Diabetes Management leads By Therapeutic Area at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Prescription Digital Therapeutics (PDT) Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Area 5
End User 5
Delivery Platform 5
Reimbursement Model 5
Technology Type 5
Companies profiled
Pear Therapeutics
Akili Interactive Labs
Click Therapeutics
Omada Health
Propeller Health (ResMed)
Happify Health
Kaia Health
Big Health
SilverCloud Health
Mahana Therapeutics
Better Therapeutics
Biofourmis
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pear Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Akili Interactive Labs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Click Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Omada Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Propeller Health (ResMed)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Happify Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Kaia Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Big Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →SilverCloud Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mahana Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Better Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Biofourmis
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Welldoc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sandoz (Novartis)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,223M by 2033 · 9.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Diabetes Management45.4
- Chronic Pain Management17.8
- Mental Health Disorders10.8
- Cardiovascular Diseases18.6
- Respiratory Diseases7.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,136M → $2,553M · 10.7%
Europe$791.9M → $1,706M · 10.1%
Asia Pacific$723.0M → $1,643M · 10.8%
Latin America$447.6M → $924.6M · 9.5%
Middle East and Africa$344.3M → $732.2M · 9.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.652026
9.672027
9.692028
9.702029
9.712030
9.712031
9.742032
9.752033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pear Therapeutics20.9
- Akili Interactive Labs16.7
- Click Therapeutics7.4
- Omada Health9.6
- Propeller Health (ResMed)10.0
- Happify Health7.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Area28.0%
End User16.0%
Delivery Platform22.9%
Reimbursement Model9.2%
Technology Type23.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.8
- Europe22.6
- Asia Pacific21.7
- Latin America12.2
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pear Therapeutics | 80 | 80 | 73 | 83 | 73 | 75 | 77 |
| Akili Interactive Labs | 76 | 74 | 86 | 71 | 73 | 71 | 75 |
| Click Therapeutics | 66 | 72 | 72 | 85 | 71 | 84 | 75 |
| Omada Health | 79 | 60 | 76 | 69 | 66 | 71 | 70 |
| Propeller Health (ResMed) | 69 | 74 | 66 | 75 | 67 | 76 | 71 |
| Happify Health | 67 | 63 | 71 | 58 | 60 | 61 | 63 |
| Kaia Health | 52 | 45 | 59 | 45 | 41 | 60 | 50 |
| Big Health | 43 | 42 | 44 | 48 | 36 | 37 | 42 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pear Therapeutics
- Akili Interactive Labs
- Click Therapeutics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pear Therapeutics | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Akili Interactive Labs | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Click Therapeutics | ✓ | − | ✓ | ◐ | ✓ | ✓ |
| Omada Health | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Propeller Health (ResMed) | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Happify Health | ◐ | ✓ | ✓ | ◐ | − | − |
| Kaia Health | ◐ | − | ◐ | ◐ | − | − |
| Big Health | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pear Therapeutics77
2Akili Interactive Labs75
3Click Therapeutics75
4Propeller Health (ResMed)71
5Omada Health70
6Happify Health63
7Kaia Health50
8Big Health42
Competitive tiers
§8.4 · p.172 →Challenger5
Strong scale, closing on the leaders.
Pear TherapeuticsAkili Interactive LabsClick TherapeuticsOmada HealthPropeller Health (ResMed)
Contender1
Focused players with pockets of strength.
Happify Health
Niche2
Specialists in a single segment or region.
Kaia HealthBig Health
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Area in North America, then scale across Prescription Digital Therapeutics (PDT) Market — a $595M beachhead inside a $8.71B market.
Beachhead (SOM)$595Mobtainable near-term
Serviceable (SAM)$3.22Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Diabetes Management
Best fit — highest urgency & budget in Therapeutic Area.
Economic buyer75 fit
Chronic Pain Management
Strong fit — clear ROI and a fast path to value.
End user67 fit
Mental Health Disorders
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Area in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Delivery Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Area leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Prescription Digital Therapeutics (PDT) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation13%
Closed-won6%
$15.7KCAC
$69KLTV
4.4:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Prescription Digital Therapeutics (PDT) Market is a durable-growth opportunity — $7.86B by 2033, compounding at 7.7%.
TAM · 2025$4.34Btoday
TAM · 2033$7.86Bforecast
CAGR7.7%2027–2033
Cumulative$53.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.86BTotal addressable market
SAM$2.85BServiceable available market
SOM$467MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.7% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Area.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Area moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.86BLarge & growingTAM by 2033 at 7.7% CAGR
$2.85BServiceable nowreachable with today’s model
$467MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.13BBear5.0% CAGR
$7.86BBase7.7% CAGR
$10.1BBull10.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Prescription Digital Therapeutics (PDT) Market — a $3.71B market by 2033. Plan: grow share from 7.9% to 16.1%.
Market size · 2033$3.71Btotal addressable
Market CAGR3.5%2027–2033
Target share16.1%from 7.9% today
Revenue ambition$597Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 16.1% | On track |
| Revenue | $276M | $597M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.3% | 41.4% | At risk |
| Customer retention | 89.6% | 96.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Area
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Area share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $67M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Area leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Prescription Digital Therapeutics (PDT) Market conversation — a $3.74B market you can size, segment and defend in minutes.
Market size · 2033$3.74Btotal opportunity
Growth3.5%CAGR to 2033
Addressable buyers1,152+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Area
Goal Grow share in Therapeutic Area
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$63K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Pear TherapeuticsAkili Interactive LabsClick TherapeuticsOmada HealthPropeller Health (ResMed)Happify HealthKaia HealthBig Health+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Prescription Digital Therapeutics (PDT) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Prescription Digital Therapeutics (PDT) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Prescription Digital Therapeutic Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportPrescription Delivery Service Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPrescription Colored Contact Lenses Market
Market size, share, segmentation and regional forecast.
$972M market · 2025 base year
View reportPrescription Cannabidiol (CBD) Oil Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportPrescription Bottle Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportPre-Scored Ampules Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportPresbyopic Glasses Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportPresbyopia Treatment Device Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportPresbyopia Solutions Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPresbyopia Prescription Lens Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportPresbyopia Corrective Intraocular Lens (PCIOL) Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportPresbyopia-Correcting IOLs Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.